BackNektar Therapeutics Overview
Nektar Therapeutics

Nektar Therapeutics Target Price

Where could NKTR trade next? Consensus target price: $120.

Get informed when a big investor buys or sells

+ Follow

Share Price

$43.58

Average Target Price

$117.67170% upside

3 analysts in the last 4 months

High: $153 | Low: $50

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-01JefferiesRoger Song$150244.2% upsideOpen
2026-09-23Wedbush$5014.7% upsideOpen
2026-07-22Canaccord GenuityEdward Nash$153251.1% upsideOpen
2026-05-11WedbushMartin Fan$8083.6% upsideOpen
2026-05-08Piper SandlerYasmeen Rahimi$192340.6% upsideOpen
2026-04-21Wedbush$95118% upsideOpen
2026-04-20H.C. Wainwright$185324.5% upsideOpen
2026-03-13OppenheimerJay Olson$140221.2% upsideOpen
2026-02-10BTIG$151246.5% upsideOpen
2026-02-10H.C. Wainwright$165278.6% upsideOpen
2026-01-26Piper SandlerYasmeen Rahimi$105140.9% upsideOpen
2025-12-16H.C. Wainwright$135209.8% upsideOpen
2025-12-16OppenheimerJay Olson$115163.9% upsideOpen
2025-11-24JefferiesRoger Song$121177.7% upsideOpen
2025-09-18JefferiesRoger Song$99127.2% upsideOpen
2022-04-18Mizuho SecuritiesMara Goldstein$686.2% downsideOpen
2022-03-01J.P. MorganJessica Fye$1761% downsideOpen
2021-11-08Ladenburg Thalmann & Co.Aydin Huseynov$2054.1% downsideOpen
2021-05-18Goldman SachsChris Shibutani$2444.9% downsideOpen

Nektar Therapeutics (NKTR) FAQ

Nektar Therapeutics's target price stands at $120. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $120 for NKTR implies 170.0% upside versus today's price ($43.58). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Nektar Therapeutics's target price evolved across reporting periods, while the comparison chart places NKTR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Nektar Therapeutics's reading of $120 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.